The 10b5-1 plan context and the consistent daily selling pattern since August 2026 suggest this is a scheduled diversification program rather than a reactive insider sale. Monitor for any change in the pace or size of daily sales, which could signal a shift in insider sentiment.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $601.32entry
- T+1 · 13d ago +1.19%α −0.46% · $608.49
- T+5 · 7d ago −2.11%α −1.53% · $588.61
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director and officer Martine Rothblatt filed a Form 144 notice of intent to sell 119,410 shares of United Therapeutics common stock, with an estimated aggregate market value of approximately $71.5 million. The filing indicates these sales are part of a pre-arranged 10b5-1 trading plan, and Rothblatt has been executing daily sales of 9,500 shares since August 2026 under that plan.
Key Facts
- Martine Rothblatt, a director and officer of United Therapeutics, filed a Form 144 on 2026-11-02.
- The proposed sale covers 119,410 shares of common stock, with an estimated market value of $71,493,155.20.
- The filing explicitly references a 10b5-1 trading plan, with daily sales of 9,500 shares occurring since August 2026.
- Rothblatt has been executing these sales consistently from August through October 2026, with each day's sale valued between approximately $4.5M and $5.7M.
- The filing notes that shares are being sold by Martine Rothblatt and/or the Martine Rothblatt Property Management Trust, which is beneficially owned by Rothblatt.
Financial Impact
Proposed sale of 119,410 shares valued at approximately $71.5 million, representing about 0.28% of the $25.5B market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur or may differ in size.
- Insider selling, even under a 10b5-1 plan, can create overhang perception if the market views the volume as large relative to average daily trading volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010587 |
| Document: 0001950047-26-010587-index.html | 0001950047-26-010587 |
| Document: 0001950047-26-010587.txt | 0001950047-26-010587 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers